What Changed at Veracyte

Every material change AI Health Index has tracked at Veracyte: new modules, model and architecture updates, clinical evidence, regulatory status, security certifications, and integration depth. Each entry states what changed, cites its source, and carries our read on what it means for a buyer. The graded assessment of this vendor across all fifteen capability axes sits on its index profile.

Funding rounds, valuations, and awards are not product changes and are not logged here. Acquisitions appear only where there is direct product impact.

Impact
Type
1 entry
Showing changes for Veracyte only.Show the full log

September 2026

V
Veracyte
Sep 14, 2026
MediumVerified
Acquisition / corporate

Veracyte acquired Convergent Genomics, adding the UroAmp urine tumor DNA test to its urology portfolio. Veracyte can now offer genomic testing from urine, tissue and blood across bladder cancer care.

Our read

A urine test can help monitor bladder cancer between cystoscopies, the procedure patients most want to avoid. Urologists should ask how UroAmp results will be reported alongside Veracyte's existing tests, and whether ordering stays the same during the integration.

Related axis: Setting and Specialty CoverageVendor announcementView source